Wistar Institute Melanoma (WM) PDX Models
Inotiv offers the Wistar Institute Melanoma (WM) PDX model collection established from targeted therapy relapsed melanoma patients, spanning BRAF inhibitors, BRAK/MEK inhibitors, immune checkpoint inhibitors and targeted therapy and immunotherapy (TT/IT) combinations. Narrow down the cells that are right for your study below.
Order today
Wistar Institute Melanoma (WM) PDX models
| Number | Age / Gender | Details |
|---|---|---|
| WM3927 | 58 F | Biopsy site: SQ Primary tumor type: SSM Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: None Mutation: BRAFV600K RPPA: NA |
| WM3934 | 75 F | Biopsy site: Pleural fluid Primary tumor type: NMM Stage at Bx: IV Targeted therapy prior to Bx: Vemurafenib, PD Immune therapy prior to Bx: None Mutation: BRAFV600E RPPA: NA |
| WM3940 | 71 M | Biopsy site: SQ Primary tumor type: MULTIPLE PRIMARIES Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: None Mutation: BRAFV600E RPPA: NA |
| WM4070-1 | 59 F | Biopsy site: SQ Primary tumor type: Unknown primary Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: None Mutation: BRAFV600K RPPA: 76, submitted |
| WM4237 | 28 F | Biopsy site: BRAIN Primary tumor type: Unknown primary Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab , PD Mutation: BRAFV600E RPPA: 102 |
| WM4007 | 63 M | Biopsy site: MET Primary tumor type: NA Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab , PD Mutation: BRAFV600E RPPA: 75,102, submitted |
| WM3901-1 | 64 M | Biopsy site: SQ Primary tumor type: NA Stage at Bx: IV Targeted therapy prior to Bx: vemurafenib, isolated progression, post sample to WM4007 Immune therapy prior to Bx: None Mutation: BRAFV600E RPPA: 75 Notes: Krepler et al., 2016 Clin Cancer Res; 22(7) April 1, 2016. Per CK: BRAF-R= BRAF-Resistant, probably the most popular, treated with Standard of Care targeted therapy. |
| WM3936-2 | 70 F | Biopsy site: SQ Primary tumor type: SSM Stage at Bx: IV Targeted therapy prior to Bx: dabrafenib, PR, PFS 39 weeks, OS 97.6 weeks Immune therapy prior to Bx: None Mutation: BRAFV600E NRASQ61K RPPA: 70,76,96, submitted Notes: Krepler et al., 2016 Clin Cancer Res; 22(7) April 1, 2016. Per CK: BRAF-R= BRAF-Resistant, probably the most popular, treated with Standard of Care targeted therapy. |
| WM3965-2 | 37 F | Biopsy site: PAROTID Primary tumor type: SSM Stage at Bx: IV Targeted therapy prior to Bx: vemurafenib, PR, PFS 14.7 weeks, OS 61.1 weeks Immune therapy prior to Bx: None Mutation: BRAFV600E RPPA: 76,96, submitted Notes: Krepler et al., 2016 Clin Cancer Res; 22(7) April 1, 2016. Per CK: BRAF-R= BRAF-Resistant, probably the most popular, treated with Standard of Care targeted therapy. |
| WM4071-1 | 77 M | Biopsy site: MET Primary tumor type: MULTIPLE PRIMARIES Stage at Bx: IV Targeted therapy prior to Bx: vemurafenib, mixed response, PFS 46.7 weeks, OS 58.7 weeks Immune therapy prior to Bx: None Mutation: BRAFV600E RPPA: 76,83, submitted Notes: Krepler et al., 2016 Clin Cancer Res; 22(7) April 1, 2016. Per CK: BRAF-R= BRAF-Resistant, probably the most popular, treated with Standard of Care targeted therapy. |
| WM4071-2 | 77 M | Biopsy site: BRAIN Primary tumor type: MULTIPLE PRIMARIES Stage at Bx: IV Targeted therapy prior to Bx: vemurafenib, mixed response, PFS 46.7 weeks, OS 58.7 weeks Immune therapy prior to Bx: None Mutation: BRAFV600E RPPA: 76,83, submitted Notes: Krepler et al., 2016 Clin Cancer Res; 22(7) April 1, 2016. Per CK: BRAF-R= BRAF-Resistant, probably the most popular, treated with Standard of Care targeted therapy. |
| WM3983 | 93 F | Biopsy site: SQ Primary tumor type: SSM Stage at Bx: IV Targeted therapy prior to Bx: vemurafenib, isolated progression, PFS 29.6 weeks, OS 86 weeks Immune therapy prior to Bx: None Mutation: BRAFV600K NRASQ61K RPPA: 70,76,96, submitted Notes: Krepler et al., 2016 Clin Cancer Res; 22(7) April 1, 2016. Per CK: BRAF-R= BRAF-Resistant, probably the most popular, treated with Standard of Care targeted therapy. |
| WM3915-2 | 65 M | Biopsy site: SQ Primary tumor type: SSM Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: Leukine, PD; Ipilimumab, PD Mutation: NRASQ61H RPPA: NA |
| WM3974 | 63 F | Biopsy site: SQ Primary tumor type: MUCOSAL Stage at Bx: IV Targeted therapy prior to Bx: Dasatinib, PR Immune therapy prior to Bx: None Mutation: NRAS G12A KIT L576P RPPA: 102 |
| WM4208 | 53 M | Biopsy site: LN Primary tumor type: NMM Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab, PD Mutation: NRASQ61R RPPA: 102 |
| WM4224 | 75 M | Biopsy site: LN Primary tumor type: NMM Stage at Bx: IIIB Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab, PR Mutation: NRASQ61R RPPA: 102 |
| WM4231-2 | 77 F | Biopsy site: LN Primary tumor type: NMM Stage at Bx: III Targeted therapy prior to Bx: None Immune therapy prior to Bx: None Mutation: NRASQ61R BRAFV624F RPPA: 102 |
| WM4082 | 59 M | Biopsy site: MET Primary tumor type: NMM Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: CD40 agonist + Tremelimumab, PR Mutation: NF1 P1084L RPPA: NA |
| WM4099 | 62 F | Biopsy site: SQ Primary tumor type: SSM Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab, d/c due to toxicity Mutation: NF1 Q1341X RPPA: NA |
| WM4281 | 75 M | Biopsy site: SQ Primary tumor type: SSM Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab, PD Mutation: NF1 RPPA: NA |
| WM4314-1 | 72 M | Biopsy site: SQ Primary tumor type: NMM Stage at Bx: III Targeted therapy prior to Bx: None Immune therapy prior to Bx: None Mutation: NF1 Q236X RPPA: submitted |
| WM3988-1 | 71 M | Biopsy site: LN Primary tumor type: MUCOSAL Stage at Bx: IIIC Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab, PD Mutation: WT RPPA: NA |
| WM4039-2 | 45 M | Biopsy site: LOCAL RECURRENCE Primary tumor type: MUCOSAL Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab, PD Mutation: WT RPPA: NA |
| WM4254 | 69 M | Biopsy site: SPINE Primary tumor type: LMM Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab, PD, Anti-PD1, PD Mutation: WT RPPA: 102 |
| WM4263 | 42 F | Biopsy site: SPINE Primary tumor type: Unknown primary Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab, PD Mutation: WT RPPA: 102 |
| WM3921 | 61 M | Biopsy site: MET Primary tumor type: Amelanotic Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: None Mutation: WT RPPA: NA |
| WM3924 | 63 M | Biopsy site: Wide Excision, L chest wall Primary tumor type: Back, Probably Nodular Stage at Bx: None Targeted therapy prior to Bx: High dose il2, PR; Tremelimumab/CD40- received 1 dose of Treme and 2 doses of CP 870,893, PD Immune therapy prior to Bx: NRASQ61K Mutation: RPPA: |
| WM4314-2 | 72 M | Biopsy site: right axillary LN recurrence Primary tumor type: Right mid back, nodular Stage at Bx: None Targeted therapy prior to Bx: on ipi start 9/17/14 Immune therapy prior to Bx: submitted Mutation: RPPA: |
| WM3907-1 | 62 F | Biopsy site: Right frontal craniotomy Primary tumor type: Stage at Bx: off PLX4032 3d, brain met Targeted therapy prior to Bx: Immune therapy prior to Bx: BRAFV600E Mutation: 75 RPPA: Krepler et al., 2016 Clin Cancer Res; 22(7) April 1, 2016. |
| WM3973 | 61 Male | Biopsy site: FNA Primary tumor type: Stage at Bx: post PLX Targeted therapy prior to Bx: now on ipi (3/13), SD Immune therapy prior to Bx: BRAFV600E HOM Mutation: 70,83 RPPA: Krepler et al., 2016 Clin Cancer Res; 22(7) April 1, 2016. |
| WM3903-1 | 61 M | Biopsy site: skin Primary tumor type: Stage at Bx: relapsed still on PLX4032 Targeted therapy prior to Bx: Immune therapy prior to Bx: BRAFV600E Mutation: 75 RPPA: Krepler et al., 2016 Clin Cancer Res; 22(7) April 1, 2016. |
Subscribe to updates from Inotiv
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
